Top Markets
#1 Black Phoenix Black Phoenix +167.29%
#2 Islamic Coin Islamic Coin +158.02%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +40.77%
#5 Cryptopia Cryptopia +21.79%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +18.71%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#8 wojak wojak +13.88%
#9 Playnance Playnance +13.30%
#10 Test Test +11.66%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
RenovaCare, Inc. RenovaCare, Inc.

RenovaCare, Inc.

RCAR
Rank in Stocks #41860
RenovaCare, Inc., a development-stage biotech and medical device company,... RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name RenovaCare, Inc.,to RenovaCare, Inc. in January 2014. RenovaCare, Inc. was incorporated in 1983 and is based in Scottsdale, Arizona.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$8.74K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade RenovaCare, Inc. (RCAR)

Category

Healthcare
Revenue for RenovaCare, Inc. (RCAR)
Revenue in Aug 2026 TTM: 0
According to RenovaCare, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for RenovaCare, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE